JP2021523126A5 - - Google Patents
Info
- Publication number
- JP2021523126A5 JP2021523126A5 JP2020561795A JP2020561795A JP2021523126A5 JP 2021523126 A5 JP2021523126 A5 JP 2021523126A5 JP 2020561795 A JP2020561795 A JP 2020561795A JP 2020561795 A JP2020561795 A JP 2020561795A JP 2021523126 A5 JP2021523126 A5 JP 2021523126A5
- Authority
- JP
- Japan
- Prior art keywords
- months
- composition according
- accumulated
- pathological tau
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666459P | 2018-05-03 | 2018-05-03 | |
| US62/666,459 | 2018-05-03 | ||
| PCT/US2019/030184 WO2019213245A1 (en) | 2018-05-03 | 2019-05-01 | Methods for reducing accumulated pathologic tau protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523126A JP2021523126A (ja) | 2021-09-02 |
| JP2021523126A5 true JP2021523126A5 (cg-RX-API-DMAC7.html) | 2022-05-10 |
Family
ID=66530499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561795A Pending JP2021523126A (ja) | 2018-05-03 | 2019-05-01 | 蓄積した病理学的Tauタンパク質を低減する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20210137861A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3787750A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021523126A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019213245A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12076330B2 (en) | 2018-04-27 | 2024-09-03 | The Regents Of The University Of California | Inhibition of lipofuscin aggregation by molecular tweezers |
| JP2021522282A (ja) | 2018-04-27 | 2021-08-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | リソソーム蓄積障害の治療 |
| EP4110315A4 (en) * | 2020-02-24 | 2024-03-06 | Oblato, Inc. | Compositions and methods for treating cancer and tumor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE335007T1 (de) * | 1993-12-21 | 2006-08-15 | Innogenetics Nv | Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen |
| US5488145A (en) * | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
| MXPA05004828A (es) * | 2002-11-07 | 2006-01-27 | Applied Neurosolutions Inc | Metodos para predecir si sujetos con deterioro cognoscitivo leve (mci) desarrollaran o no la enfermedad de alzheimer. |
| CA2772097C (en) * | 2009-08-24 | 2019-04-30 | Hough Ear Institute | Methods for treating acute acoustic trauma |
| WO2012106654A1 (en) * | 2011-02-04 | 2012-08-09 | Hough Ear Institute | Methods for treating brain injury |
| US20140249180A1 (en) * | 2011-10-03 | 2014-09-04 | National Center For Geriatrics And Gerontology | Tau aggregation inhibitor |
| WO2017048778A1 (en) * | 2015-09-18 | 2017-03-23 | Oklahoma Medical Research Foundation | Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier |
| US10576125B2 (en) * | 2016-10-31 | 2020-03-03 | Hough Ear Institute | Methods for enhancing synaptogenesis and neuritogenesis |
-
2019
- 2019-05-01 WO PCT/US2019/030184 patent/WO2019213245A1/en not_active Ceased
- 2019-05-01 JP JP2020561795A patent/JP2021523126A/ja active Pending
- 2019-05-01 US US17/052,093 patent/US20210137861A1/en active Pending
- 2019-05-01 EP EP19723991.6A patent/EP3787750A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Murphy et al. | Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease | |
| Roberts et al. | Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis | |
| JP2019537582A5 (cg-RX-API-DMAC7.html) | ||
| Bates et al. | Ototoxicity induced by gentamicin and furosemide | |
| Kornblut et al. | Ear disease in patients with Wegener's granulomatosis | |
| JP2011527339A5 (cg-RX-API-DMAC7.html) | ||
| Petejova et al. | Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients. | |
| JP2019524834A5 (cg-RX-API-DMAC7.html) | ||
| JP2025060686A5 (cg-RX-API-DMAC7.html) | ||
| JP2018522938A (ja) | 難聴の処置のためのセトロンファミリーのカルシニューリン阻害剤 | |
| US12121513B2 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
| JP2015523346A5 (cg-RX-API-DMAC7.html) | ||
| DOP2021000015A (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
| JP2018505218A5 (cg-RX-API-DMAC7.html) | ||
| JP2020504154A5 (cg-RX-API-DMAC7.html) | ||
| US20250000795A1 (en) | Treatment of sepsis and septic shock | |
| JP2020527138A5 (cg-RX-API-DMAC7.html) | ||
| US20210137861A1 (en) | Methods for reducing accumulated pathologic tau protein | |
| CN117651556A (zh) | 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案 | |
| RU2220730C2 (ru) | Способ лечения герпетического стоматита | |
| JP2023521161A5 (cg-RX-API-DMAC7.html) | ||
| JP2024526880A5 (cg-RX-API-DMAC7.html) | ||
| JP2026501711A (ja) | 聴覚障害の治療のための併用療法 | |
| IL313067A (en) | Methods of treating neurological disorders | |
| Akingbola et al. | Therapeutic plasma exchange in the management of myasthenia crisis in a resource poor setting |